---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic burden and healthcare resource utilization. Topics: Cost increase at progression to castration resistance; Costs during first-line therapy: commercial, Medicare Advantage, and Medicaid claims; Medicare fee-for-service resource use by line of therapy; Medicare fee-for-service costs by line of therapy; 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Cost increase at progression to castration resistance

> “Among 296 patients with mCSPC progressing to mCRPC (median age 69.0 years, 60.5% White, 15.9% Black)”
> “The mean number of days with PC-related outpatient visits increased from 1.57 to 2.16 PPPM in the mCSPC and mCRPC disease states (P < 0.001). From the mCSPC to mCRPC disease states, mean all-cause total health care costs PPPM increased from $4,424 (medical costs: $2,846) to $9,717 (medical costs: $4,654), and mean PC-related total health care costs PPPM increased from $2,859 (medical costs: $1,626) to $8,012 (medical costs: $3,285; all P < 0.001).”

Source: [Kaye et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11217864/)

<a id="topic-2.2.1.8.2-2"></a>

### Costs during first-line therapy: commercial, Medicare Advantage, and Medicaid claims

> “Among 459 patients with mCRPC (mean age 70 years, 57% White, 16% Black, 45% commercially-insured, 43% Medicare Advantage-insured, and 12% Medicaid-insured), average baseline all-cause total costs (PPPM) were $4,576 ($4,166 pre-mCRPC progression, $8,278 post-mCRPC progression).”
> “During an average 1 L duration of 8.5 months, mean total costs were $13,746 (all-cause) and $12,061 (PC-related) PPPM.”
> “PC-related medical costs PPPM increased from $1,504 during baseline to $5,585 following 1 L mCRPC therapy initiation.”

Source: [Kaye et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38204397/)

<a id="topic-2.2.1.8.2-3"></a>

### Medicare fee-for-service resource use by line of therapy

> “A total of 14,780 men with mCRPC were identified. After mCRPC diagnosis, 11,528 men initiated 1L mCRPC therapy, 6275 initiated 2L, and 2945 initiated 3L.”
> “All-cause medical HRU (days PPPY) increased after mCRPC diagnosis and from 1L through 3L treatment, particularly for outpatient care (pre-diagnosis, 10.4; 1L, 16.2; 2L, 18.9; 3L, 22.0) and physician/other visits (pre-diagnosis, 30.1; 1L, 46.5; 2L, 50.2; 3L, 56.9).”
> “After mCRPC diagnosis, 11,528 (78%) patients received life-prolonging therapy and 3252 (22%) patients did not.”

Source: [Freedland et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10500004/)

<a id="topic-2.2.1.8.2-4"></a>

### Medicare fee-for-service costs by line of therapy

| Period | All-cause medical and pharmacy, mean per patient per year (2019 USD) | Prostate cancer-related medical, mean per patient per year (2019 USD) |
| --- | --- | --- |
| Year before mCRPC diagnosis | “27,468” | “11,411” |
| After mCRPC diagnosis, all patients | “124,379” | “52,609” |
| After diagnosis, no life-prolonging therapy | “102,380” | “51,076” |
| First line | “148,325” | “69,063” |
| Second line | “160,118” | “73,467” |
| Third line | “165,186” | “95,240” |

Source: [Freedland et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10500004/)

<a id="topic-2.2.1.8.2-5"></a>

### Older Medicare beneficiaries: resource use and costs per patient-year

> “A total of 4758 patients met the eligibility criteria and received 1L treatment.”
> “On average, patients had 1.2 inpatient admissions, 1.1 emergency room visits, and 27.6 outpatient visits per year during follow-up. The mean total all-cause and PC-related costs during the follow-up period were $111,060 and $99,540 per-patient-per-year, respectively.”

Source: [Swami et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37248148/)

<a id="topic-2.2.1.8.2-6"></a>

### Second androgen receptor pathway inhibitor or taxane after a first: resource use in Medicare

> “Patients with mCRPC who previously received one androgen receptor pathway inhibitor (ARPI) followed by either a second ARPI (ARPI cohort) or a taxane (taxane cohort) were included.”
> “Of 923 patients, 714 were in the ARPI cohort and 209 in the taxane cohort.”
> “Median OS was ≈1 year in both cohorts. SAEs were more frequent in the taxane cohort (66.0% vs 42.2%; p < 0.001). The taxane cohort had more ER, outpatient, and pharmacy visits (p < 0.0001), while the ARPI cohort had more hospitalizations (p < 0.0001).”

Source: [McKay et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42836510/)

<a id="topic-2.2.1.8.2-7"></a>

### Taxane adverse event costs after first-line androgen receptor pathway inhibitor

> “Overall, 2L ARPI (n = 473) vs. taxane (n = 214) was associated with longer median OS (15.4 vs. 13.6 months).”
> “Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334).”
> “Overall, only 22% of patients in the Flatiron cohort and 13% in the PharMetrics cohort received > 8 cycles of taxanes, while 78% and 87%, respectively, were early discontinuers.”

Source: [Shore et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13401553/)

<a id="topic-2.2.1.8.2-8"></a>

### Insurer drug payments by first-line agent: employer-sponsored insurance

> “This retrospective cohort study included 4,298 patients with prostate cancer who initiated therapy with one of six drugs approved for first-line treatment of mCRPC between July 1, 2013, and June 30, 2019.”
> “Over the 6 months after the index prescription, mean unadjusted gross drug payments were highest for patients receiving sipuleucel-T ($115,525 USD) and lowest for patients using docetaxel ($12,804 USD).”

Source: [Kaye et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10113111/)

<a id="topic-2.2.1.8.2-9"></a>

### Skeletal-related events: attributable Medicare cost

> “HCRU and costs (in 2013 U.S. dollars) were evaluated in a propensity score-matched cohort by using Poisson regression and Kaplan-Meier sample average estimators, respectively.”
> “Among 3,297 men with prostate cancer metastatic to bone, 40% experienced ≥1 SRE (median follow-up, 19 months).”
> “Among men with ≥1 SRE, emergency department visits were twice as frequent (95% CI, 1.77–2.28) and hospitalizations were nearly four times as frequent (95% CI, 3.20–4.40). The attributable cost of ≥1 SRE was $21,191 (≥1 SRE: $72,454 [95% CI, $67,362–$76,958]; SRE-free: $51,263 [95% CI, $45,439–$56,100]).”

Source: [McDougall et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786354/)

Additional sources: [Hagiwara et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23146970/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
